A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea-Reference-Cited by-同舟云学术

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Published:2013-10-30 Issue:4 Volume:120 Page:513-520
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Verstovsek Srdan¹,Passamonti Francesco²,Rambaldi Alessandro³,Barosi Giovanni⁴,Rosen Peter J.⁵,Rumi Elisa⁴,Gattoni Elisabetta⁶,Pieri Lisa⁷,Guglielmelli Paola⁷,Elena Chiara⁴,He Shui⁸,Contel Nancy⁸,Mookerjee Bijoyesh⁸,Sandor Victor⁸,Cazzola Mario⁴⁹,Kantarjian Hagop M.¹,Barbui Tiziano³,Vannucchi Alessandro M.⁷

Affiliation:

1. Department of Leukemia Division of Cancer MedicineThe University of Texas MD Anderson Cancer CenterHouston Texas

2. Division of Hematology, Department of Internal Medicine, Ospedali di Circolo e Fondazione Macchi Varese Italy

3. Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIIIBergamo Italy

4. Department of Hematology OncologyFondazione IRCCS Policlinico San MatteoPavia Italy

5. Tower Cancer Research FoundationBeverly Hills California

6. Department of Oncology, Ospedale Santo SpiritoCasale Monferrato Italy

7. Department of Experimental and Clinical Medicine, University of FlorenceFlorence Italy

8. Incyte CorporationWilmington Delaware

9. Department of Molecular Medicine, University of PaviaPavia Italy

Funder

Incyte Corporation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.28441

Reference31 articles.

1. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

2. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

3. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

4. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

5. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera;Journal of Clinical Medicine;2024-08-22

2. Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century;Annals of Hematology;2024-04-09

3. A safety evaluation of ruxolitinib for the treatment of polycythemia vera;Expert Opinion on Drug Safety;2023-12-29

4. Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care;American Journal of Health-System Pharmacy;2023-08-09

5. Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera;Expert Review of Hematology;2023-04-05